ARTICLE | BGBx The Execution Gap Why Pharma Brand Teams Are Struggling To Keep Pace And How To Move Forward Authors: Drew Bustos, Chief Growth Officer, BGBx Broderick Crosland,...
Read More
ARTICLE | Featured in MM+M Access Is No Longer Just a Market Access Problem by: Dane Schroeder, EVP, Payer & Access Communications, BGBx Patient access has become a commercial...
Read More
ARTICLE | BGBx & Hayden Why Market Access Just Became Oncology Marketing's Biggest Anxiety Authors: David MacDougall, Managing Director and Co-Founder, Hayden Consulting Group Jamie Sidore, Managing Director and...
Read More
ARTICLE | BGBx Procurement’s Expanding Role in Pharma Marketing What parallel surveys of procurement and the brand teams they serve reveal about the gap between them By Drew Bustos,...
Read More
BLOG | Consulting | AI and Innovation Strategy Blood Biomarkers in Alzheimer's Disease
Read More
BLOG | Consulting | Market Access Blood Biomarkers in Alzheimer's Disease
Read More
BLOG | Consulting | Innovation & Intelligence Why AI Isn't Solving Go-to-Market Failure in Pharma — and What Actually Will Explore Our Insights
Read More
BLOG | Consulting | Market Access 2026 Oncology Market Access Trends The oncology access landscape is increasingly shaped by a dynamic “tug of war” between payer-driven cost controls...
Read More
BLOG | Consulting | Pricing and Policy Strategy Implications of the IRA’s Maximum Fair Price (MFP) Negotiations The Inflation Reduction Act created Maximum Fair Price (MFP), a pathway...
Read More
BLOG | Consulting | Pricing and Policy Strategy 340B Drug Discount Program The 340B drug discount program was created in 1992 to lower outpatient drug costs for healthcare...
Read More